esc guidelines: oral antiplatelet therapy before and in ... · 9 recommendations for platelet...
TRANSCRIPT
![Page 1: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/1.jpg)
ESC Guidelines: oral antiplatelet therapy before and in the cathlab (in ACS)
Steen D. Kristensen, MD, DMSc, FESC
Professor of Cardiology
Aarhus Universiity Hospital
Denmark
![Page 2: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/2.jpg)
Conflicts of interest
• AstraZeneca, Aspen and Bayer (Speakers fee).
Steen D. Kristensen
![Page 3: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/3.jpg)
Fibrinogen
GP IIb/IIIa
--
ClopidogrelPrasugrelTicagrelorCangrelor
Aspirin
-GP IIb/IIIa Inhibitors
COXADP
Activation
AggregationIV
Oral
Antiplatelet therapy
-PAR-1
Vorapaxar
COX = cyclooxygenase enzyme; GP = glycoprotein; IV = intravenous; PAR-1 = Protease-activated receptor. Hamm CW. Personal communication.
![Page 4: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/4.jpg)
Oral antiplatelets before and in the cath lab
4
ESC STEMI GL 2012
ESC MYOCARDIAL REVASCULARIZATION GL 2014
ESC NSTEMI GL 2015
![Page 5: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/5.jpg)
www.escardio.org
Initial assessment of patients with suspected acute coronary syndromes
5
Echo
![Page 6: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/6.jpg)
www.escardio.org
6
Selection of NSTE-ACS treatment strategy and timing according to initial risk stratification
![Page 7: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/7.jpg)
Recommendations for platelet inhibition in NSTE-ACS
Recommendations Classa Levelb
Oral antiplatelet therapy
Aspirin is recommended for all patients without contra-indications at an initial oral loading dosec of 150–300 mg (in
aspirin-naïve patients) and a maintenance dose of 75–100 mg daily long-term regardless of treatment strategy. I A
A P2Y12 inhibitor is recommended, in addition to aspirin, for 12 months unless there are contraindications such as
excessive risk of bleeds.
• Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended, in the absence of contraindicationsd, for all
patients at moderate- to high-risk of ischaemic events (e.g. elevated cardiac troponins), regardless of initial treatment
strategy and including those pretreated with clopidogrel (which should be discontinued when ticagrelor is started).
• Prasugrel (60 mg loading dose, 10 mg daily dose) is recommended in patients who are proceeding to PCI if no
contraindication.d
• Clopidogrel (300–600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive
ticagrelor or prasugrel or who require oral anticoagulation.
I A
I B
I B
I B
P2Y12 inhibitor administration for a shorter duration of 3–6 months after DES implantation may be considered in
patients deemed at high bleeding risk.IIb A
It is not recommended to administer prasugrel in patients in whom coronary anatomy is not known. III B
Intravenous antiplatelet therapy
GPIIb/IIIa inhibitors during PCI should be considered for bailout situations or thrombotic complications. IIa C
Cangrelor may be considered in P2Y12 inhibitor-naïve patients undergoing PCI. IIb A
![Page 8: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/8.jpg)
Recommendations for platelet inhibition in NSTE-ACS
Recommendations Classa Levelb
Oral antiplatelet therapy
Aspirin is recommended for all patients without contra-indications at an initial oral loading dosec of 150–300 mg (in
aspirin-naïve patients) and a maintenance dose of 75–100 mg daily long-term regardless of treatment strategy. I A
A P2Y12 inhibitor is recommended, in addition to aspirin, for 12 months unless there are contraindications such as
excessive risk of bleeds.
• Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended, in the absence of contraindicationsd, for all
patients at moderate- to high-risk of ischaemic events (e.g. elevated cardiac troponins), regardless of initial treatment
strategy and including those pretreated with clopidogrel (which should be discontinued when ticagrelor is started).
• Prasugrel (60 mg loading dose, 10 mg daily dose) is recommended in patients who are proceeding to PCI if no
contraindication.d
• Clopidogrel (300–600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive
ticagrelor or prasugrel or who require oral anticoagulation.
I A
I B
I B
I B
P2Y12 inhibitor administration for a shorter duration of 3–6 months after DES implantation may be considered in
patients deemed at high bleeding risk.IIb A
It is not recommended to administer prasugrel in patients in whom coronary anatomy is not known. III B
Intravenous antiplatelet therapy
GPIIb/IIIa inhibitors during PCI should be considered for bailout situations or thrombotic complications. IIa C
Cangrelor may be considered in P2Y12 inhibitor-naïve patients undergoing PCI. IIb A
![Page 9: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/9.jpg)
9
Recommendations for platelet inhibition in NSTE-ACS 2015
Recommendations Class Level
Oral antiplatelet therapy
A P2Y12 inhibitor is recommended, in addition to aspirin, for 12 months unless there are contraindications such as
excessive risk of bleeds.
• Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended, in the absence of contraindicationsd, for all
patients at moderate- to high-risk of ischaemic events (e.g. elevated cardiac troponins), regardless of initial treatment
strategy and including those pretreated with clopidogrel (which should be discontinued when ticagrelor is started).
• Prasugrel (60 mg loading dose, 10 mg daily dose) is recommended in patients who are proceeding to PCI if no
contraindication.
• Clopidogrel (300–600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive ticagrelor or
prasugrel or who require oral anticoagulation.
I A
I B
I B
I B
Roffi M, et al. Eur Heart J 2015; Epub ahead of print.
![Page 10: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/10.jpg)
Recommendations for platelet inhibition in NSTE-ACS
Recommendations Classa Levelb
Oral antiplatelet therapy
Aspirin is recommended for all patients without contra-indications at an initial oral loading dosec of 150–300 mg (in
aspirin-naïve patients) and a maintenance dose of 75–100 mg daily long-term regardless of treatment strategy. I A
A P2Y12 inhibitor is recommended, in addition to aspirin, for 12 months unless there are contraindications such as
excessive risk of bleeds.
• Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended, in the absence of contraindicationsd, for all
patients at moderate- to high-risk of ischaemic events (e.g. elevated cardiac troponins), regardless of initial treatment
strategy and including those pretreated with clopidogrel (which should be discontinued when ticagrelor is started).
• Prasugrel (60 mg loading dose, 10 mg daily dose) is recommended in patients who are proceeding to PCI if no
contraindication.d
• Clopidogrel (300–600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive
ticagrelor or prasugrel or who require oral anticoagulation.
I A
I B
I B
I B
P2Y12 inhibitor administration for a shorter duration of 3–6 months after DES implantation may be considered in
patients deemed at high bleeding risk.IIb A
It is not recommended to administer prasugrel in patients in whom coronary anatomy is not known. III B
Intravenous antiplatelet therapy
GPIIb/IIIa inhibitors during PCI should be considered for bailout situations or thrombotic complications. IIa C
Cangrelor may be considered in P2Y12 inhibitor-naïve patients undergoing PCI. IIb A
![Page 11: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/11.jpg)
www.escardio.org
Timing of P2Y12 Inhibitor Initiation
• As the optimal timing of ticagrelor or clopidogrel
administration in NSTE-ACS patients scheduled for
an invasive strategy has not been adequately
investigated, no recommendation for or against
pretreatment with these agents can be formulated.
Based on the ACCOAST results, pretreatment with
prasugrel is not recommended.
![Page 12: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/12.jpg)
www.escardio.org
12
Selection of NSTE-ACS treatment strategy and timing according to initial risk stratification
![Page 13: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/13.jpg)
NSTEMI - pretreatment
• Patient
• Time to catheterization
• Setting – organization – invasive strategy
Speaker
![Page 15: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/15.jpg)
Recommendation for initial diagnosis
![Page 16: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/16.jpg)
Primary PCI
![Page 17: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/17.jpg)
Logistics of pre-hospital care
![Page 18: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/18.jpg)
Periprocedural anti thrombotic medication in
primary PCI
![Page 19: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/19.jpg)
When should we start treatment with P2Y12 inhibitors?
• ASAP in all with suspected STEMI?
• Only in patients with ‘definite’ STEMI?
• After angiography when we go ahead with PCI?
Speaker
![Page 20: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/20.jpg)
www.escardio.org/guidelines European Heart Journal 2012 - doi:10.1093/eurheartj/ehs215
Doses of anti-platelet co-therapies
![Page 21: ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y](https://reader033.vdocuments.mx/reader033/viewer/2022052020/6034f0f59372b042924de55e/html5/thumbnails/21.jpg)
Oral antiplatelets before and in the cath lab
21
ESC DAPT CONSENSUS DOCUMENT 2017
ESC MYOCARDIAL REVASCULARIZATION GL 2018
ESC STEMI GL 2017
ESC STEMI GL 2012ESC MYOCARDIAL
REVASCULARIZATION GL 2014
ESC NSTEMI GL 2015